Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 4:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–44 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pharmacokinetics of Ketoconazole Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Drug Interaction Study of the Effect of Ketoconazole at Steady State on the Pharmacokinetics of a Single Dose of Isavuconazole in Healthy Adult Subjects

NCT01657838
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Pharmacokinetics of Ketoconazole, Healthy Adult Volunteers
Interventions
Isavuconazole, Ketoconazole
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Pharmacokinetic Interaction of Multiple Dose Ketoconazole on Single Dose YM178 Oral Controlled Absorption System (OCAS) in Healthy Adult Volunteers

NCT01476800
View directory record Official record
Conditions
Healthy Subjects, Pharmacokinetics of YM178
Interventions
YM178 OCAS, Ketoconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
19 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Determine The Effect Of Food And Strong CYP3A4 Enzyme Inhibitor On PF-04449913 Drug Levels

NCT01749085
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PF-04449913, ketoconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

Ketoconazole Plus Docetaxel to Treat Prostate Cancer

NCT00032825
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Ketaconazole, Docetaxel
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants

NCT01626651
View directory record Official record
Conditions
Healthy
Interventions
Ibrutinib, Ketoconazole
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Neptune City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effect of Ketoconazole on the Pharmacokinetics of GDC-0980

NCT01473316
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0980, Ketoconazole
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

NCT01340846
View directory record Official record
Conditions
Cancer
Interventions
Warfarin, Ketoconazole, Gemfibrozil, GSK2118436 150mg, GSK2118436 75mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Scottsdale, Arizona • Sarasota, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of The Repeat Dosing Of Ketoconazole On The Pharmacokinetics Of A Single Dose Of Pazopanib (GW786034) Eye Drops

NCT00659555
View directory record Official record
Conditions
Macular Degeneration
Interventions
pazopanib eye drops, Ketoconozole tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Effects of Ketoconazole Taken Orally Has on the PK Profiles of a Dose of GSK189075 in Healthy Volunteers

NCT00501397
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
Interventions
ketoconazole, GSK189075
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2012 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Estimation Of Effect Of Ketoconazole On Pharmacokinetics Of Crizotinib In Healthy Volunteers

NCT01149785
View directory record Official record
Conditions
Healthy
Interventions
crizotinib, ketoconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2011 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade

NCT00129207
View directory record Official record
Conditions
Tumors
Interventions
bortezomib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 10, 2008 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Ketoconazole on Sufentanil NanoTab Pharmacokinetics

NCT01721070
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Sufentanil NanoTab (SUF NT) 15 mcg, Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

NCT01021358
View directory record Official record
Conditions
Lymphoma, Chronic Lymphocytic Leukemia, Solid Tumors
Interventions
ABT-263, Ketoconazole
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2010 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 4 Interventional Results available

VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK

NCT01205230
View directory record Official record
Conditions
Cancer
Interventions
pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
New Brunswick, New Jersey • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated May 21, 2012 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-199

NCT01969669
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
ABT-199, Ketoconazole
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Tucson, Arizona • Lebanon, New Hampshire • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

Effect of Ketoconazole on the Pharmacokinetics of Vinflunine

NCT00388557
View directory record Official record
Conditions
Cancer
Interventions
vinflunine + ketaconazole
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 18, 2016 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of NBI-98854 in Healthy Subjects

NCT01910480
View directory record Official record
Conditions
Effect of Ketoconazole on the PK of NBI-98854 in Healthy Subjects
Interventions
NBI-98854 50 mg capsule once daily, Ketoconazole 400 mg (200 mg twice daily)
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY2484595 on Pharmacokinetics in Healthy Participants

NCT01448824
View directory record Official record
Conditions
Healthy Participants
Interventions
LY2484595, Placebo, Ketoconazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 1, 2019 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics

NCT01318265
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 2, 2014 · Synced Jun 10, 2026, 4:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Tasimelteon Alone and in Combination With a CYP3A4 Inhibitor, Ketoconazole, or a CYP3A4 Inducer, Rifampin.

NCT01637636
View directory record Official record
Conditions
Healthy
Interventions
tasimelteon, Rifampin, Ketoconazole
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 16, 2014 · Synced Jun 10, 2026, 4:21 AM EDT